^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TT11X

    i
    Other names: TT11X, TT 11X, Allogeneic CD30.CAR-EBVST, Allogeneic CD30-Chimeric Antigen Receptor Epstein-Bar Virus-Specific T cells, TT-11X
    Associations

    News

    Trials
    Company:
    Tessa Therap
    Drug class:
    CD30-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Baylor College of Medicine | Initiation date: Jun 2024 --> Jan 2025
    Trial initiation date • Virus specific T cells
    |
    TT11X
    1year
    Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Baylor College of Medicine
    New P1 trial
    |
    TT11X
    over1year
    Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=0, Withdrawn, Baylor College of Medicine | N=18 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Virus specific T cells
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X
    over1year
    Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2023 --> Jun 2025
    Trial completion date • Trial primary completion date • Virus specific T cells
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X
    2years
    Humanized CD30 chimeric antigen receptor T cells with a novel 4-1BB derived spacer have improved activity and safety against CD30-positive lymphomas​ (SITC 2022)
    Humanized CD30.CARs combined with the 4-1BB-derived spacer did not exhibit any nonspecific interactions with CD16+ immune cells, while displaying superior efficacy in vitro , better persistence in vivo in various humanized mouse models, and more importantly an improved safety profile in a leukemia model with high tumor burden. Conclusions Our re-engineered CD30.CAR construct, consisting of a humanized CD30.CAR and a 4-1BB-derived spacer, is likely to improve allogeneic CD30.CAR EBVST performance.
    Clinical • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    TT11X
    over2years
    Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=18, Recruiting, Baylor College of Medicine | Trial primary completion date: Jun 2022 --> Jun 2025
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X
    over3years
    Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Baylor College of Medicine
    Clinical • New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X
    4years
    Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=18, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X
    almost5years
    Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Baylor College of Medicine
    Clinical • New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X